Convey Holding Parent Inc

CNVY 4 | $10.51 0.0%

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (-0.5% 3d) (0.0% 7d) (239.48% volume)
Earnings Calendar:
Market Cap: $ 769,270,737
https://www.conveyhealthsolutions.com
Sec Filling | Patents | 3000 employees

Convey is a specialized healthcare technology and services company that is committed to providing clients with healthcare-specific, compliant member support solutions utilizing technology, engagement, and analytics. Convey's administrative solutions for government-sponsored health plans help to optimize member interactions, ensure compliance, and support end-to-end Medicare processes. By combining its purpose-built technology platforms with dedicated and flexible business process solutions, Convey creates better business results and better healthcare consumer experiences on behalf of business customers and partners. Convey's clients include some of the nation's leading health insurance plans and pharmacy benefit management firms. Convey's healthcare-focused teams help millions of Americans navigate the complex Medicare Advantage and Part D landscape.

optical ycombinator

add to watch list Paper trade email alert is off

iSpecimen Inc

ISPC | $0.211 -2.71% 71K

Professional, Scientific, and T...

(0.0% 1d) (-36.1% 1m) (-87.1% 1y) (0.0% 2d) (0.0% 3d) (-2.6% 7d) (-74.01% volume)
Earnings Calendar: 2024-02-21
Market Cap: $ 1,978,059

Sec Filling | Patents | 75 employees

headquartered in lexington, ma, ispecimen is the marketplace for human biospecimens, providing researchers with the specimens they need from the patients they want. the privately held company has developed the ispecimen marketplace, an online platform connecting healthcare organizations that have access to patients and specimens with the scientists who need them. proprietary, cloud-based technology enables researchers to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. researchers easily and compliantly gain access to specimens to drive scientific discovery. partner sites gain an opportunity to contribute to biomedical discovery as well as their bottom line. and ultimately, healthcare advances for all.

add to watch list Paper trade email alert is off

Lyell Immunopharma Inc

LYEL | $2.405 0.21% 0.21% 1.3M

Professional, Scientific, and T...

(0.0% 1d) (15.4% 1m) (-5.5% 1y) (0.0% 2d) (0.0% 3d) (-2.0% 7d) (-23.16% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 611,101,628
https://lyell.com
Sec Filling | Patents | 189 employees

Lyell is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. The Company focuses on addressing what it believes are the primary barriers that limit consistent, reliable and curative responses with adoptive T cell therapy: T cell exhaustion and loss of durable stemness, which includes proliferative capacity, ability to self-renew and ability to differentiate and eliminate solid tumors. Lyell is applying its proprietary ex vivo genetic and epigenetic reprogramming technology platforms, Gen-R and Epi-R, to address these barriers in order to develop new medicines with improved, durable, and potentially curative clinical outcomes. Lyell is based in South San Francisco, Seattle and Bothell, Washington.

genetic t-cell renewable

add to watch list Paper trade email alert is off

Unicycive Therapeutics Inc

UNCY | $1.09 -4.39% -4.59% 540K

Professional, Scientific, and T...

(0.0% 1d) (-20.3% 1m) (-34.9% 1y) (0.0% 2d) (0.0% 3d) (-12.3% 7d) (153.13% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 37,884,515
https://unicycive.com
Sec Filling | Patents | 2021 employees

Unicycive is a biotechnology company developing novel treatment for kidney diseases. Unicycive's lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent protected new chemical entity in late preclinical development for the treatment of acute kidney injury.

treatment kidney

add to watch list Paper trade email alert is off